The present invention is concerned with novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of anxiety and depressive disorders and other diseases. The compounds of present invention are described with the general formula (I) wherein R 1 to R 5 , R 5' , R 7 to R 9 , R 7' , R 8' , X and Y are as defined in the specification.
